注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Eyepoint Pharmaceuticals Inc是一家製藥公司。該公司的主要候選產品EYP-1901將其Durasert技術的可生物侵蝕配方與酪氨酸激酶抑製劑( TKI )vorolanib相結合,後者已顯示出抗血管內皮生長因子(VEGF)活性。該公司有兩個商業產品,YUTIQ和DEXYCU。YUTIQ是一種不可侵蝕的玻璃體內植入物,含有長達36個月的氟輕鬆(FA),適用於治療影響眼睛後段的慢性非感染性葡萄膜炎。YUTIQ利用其Durasert緩釋藥物輸送技術平台。DEXYCU是治療術後眼部炎症的指徵。DEXYCU利用其Verisome藥物遞送技術。該公司還在推進YETIQ 50,這是一種為期六個月的影響眼睛後段的非感染性葡萄膜炎治療,這是補充新藥應用(sNDA)策略下失明的原因之一。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Goran A. Ando | 74 | 2018 | Independent Non-Executive Chairman |
Jay S. Duker | 64 | 2020 | President, CEO & Director |
Nancy S. Lurker | 66 | 2016 | Executive Vice-Chairman |
Anat Loewenstein | - | 2023 | Member of Executive Scientific Advisory Board |
Anthony P. Adamis | 64 | 2022 | Independent Director |
Karen Zaderej | 61 | 2022 | Independent Director |
Stuart Duty | 58 | 2023 | Independent Director |
Wendy F. DiCicco | 57 | 2019 | Independent Director |
David Robert Guyer | 64 | 2019 | Independent Director |
Charles C. Wykoff | - | 2021 | Co-Chair of Scientific Advisory Board |
Rishi P. Singh | - | 2021 | Member of Executive Scientific Advisory Board |
Glenn J. Jaffe | - | 2021 | Member of Executive Scientific Advisory Board |
Allen C. Ho | - | 2024 | Member of Scientific Advisory Board |
David S. Boyer | - | 2021 | Member of Executive Scientific Advisory Board |
Carl D. Regillo | - | 2021 | Co- Chairman of Scientific Advisory Board |
Anna Kluczewska | - | - | CEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd |
Ye Liu | 52 | 2020 | Director |
Sophie J. Bakri | - | 2021 | Member of Executive Scientific Advisory Board |
Usha Chakravarthy | - | 2024 | Member of Scientific Advisory Board |
Frank G. Holz | - | 2024 | Member of Scientific Advisory Board |
John B. Landis | 71 | 2018 | Interim Head of R&D and Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核